Cabotegravir

Specifications

1051375-10-0CAS Number

855-453-4EC Number

(3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamideIUPAC Name

C19H17F2N3O5Chemical Formula

405.4 g/molMolecular Weight

Cabotegravir; 1051375-10-0; GSK744; GSK1265744A; Apretude; GSK744 LAP; GSK744 LA; cabotegravirum; GSK-1265744A; S-265744; GSK 744; S/GSK1265744; HMH0132Z1Q; CHEBI:172944; CABENUVA COMPONENT CABOTEGRAVIR; (3S,11aR)-N-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide; (3S,11aR)-N-((2,6-difluoropyridin-3-yl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide; (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide; (3S,11aR)-N-((2,4-Difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide; (3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide; RefChem:573195; Cabotegravir and rilpivirine; GSK1265744; Cabotegravir (GSK744, GSK1265744); GSK-1265744; MFCD25976748; (3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide; GSK 1265744; (3S,11AR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide; CAB; Vocabria (TN); UNII-HMH0132Z1Q; Cabotegravir [USAN:INN]; C19H17F2N3O5; Apretude (TN); 744 LA; Cabotegravir (Standard); Cabotegravir(GSK744); CABOTEGRAVIR [INN]; CABOTEGRAVIR [JAN]; CABOTEGRAVIR [USAN]; SCHEMBL82803; CABOTEGRAVIR [WHO-DD]; Cabotegravir (JAN/USAN/INN); orb1301075; Cabotegravir; GSK1265744; CHEMBL2403238; SCHEMBL29374458; GTPL11386; DTXSID50146982; WCWSTNLSLKSJPK-LKFCYVNXSA-N; CABOTEGRAVIR [ORANGE BOOK]; GLXC-90529; EX-A2330; Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-;Oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-, (3S,11aR)-; BDBM50492496; EBC-26970; HY-15592R; s7766; AKOS027253403; Cabenuva (cabotegravir + rilpivirine); CCG-268708; CS-5078; DB11751; NCGC00386434-02; AC-30895; AS-61279; DA-71856; FD143198; HY-15592; S/GSK1265744; GSK744; SY099595; NS00073130; T6098; D10548; P14046; EN300-7388992; Q15411012; (3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.0,3,7]trideca-9,12-diene-12-carboxamide; (3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.0?,?]trideca-9,12-diene-12-carboxamide; (3S,11aR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide; (3S,11aR)-N-[(2,4-Difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8 -carboxamide; (3S,11aR)-N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,11,11a-tetrahydrooxazolo[[?]]pyrido[[?]]pyrazine-8-carboxamide; 1264720-72-0; N-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide; OXAZOLO(3,2-A)PYRIDO(1,2-D)PYRAZINE-8-CARBOXAMIDE, N-((2,4-DIFLUOROPHENYL)METHYL)-2,3,5,7,11,11A-HEXAHYDRO-6-HYDROXY-3-METHYL-5,7-DIOXO-, (3S,11AR)-Synonyms